{
    "clinical_study": {
        "@rank": "138061", 
        "brief_summary": {
            "textblock": "To determine the frequency of delayed-type hypersensitivity (DTH) reactions in HIV-positive\n      patients to two doses of two envelope glycoprotein antigens prepared differently. To\n      determine whether patients who have previously demonstrated a DTH response to intradermal\n      MGStage HIV-1 gp160 IIIB baculovirus (MicroGeneSys) have a reproducible response to a repeat\n      injection of gp160 and whether there is cross-reactivity to intradermal HIV-1 rgp160 IIIB\n      vero cell expressed (Immuno-AG).\n\n      PER 4/5/95 AMENDMENT: To also determine whether patients who respond to HIV-1 rgp160 IIIB\n      baculovirus (MicroGeneSys) have cross-reactivity to intradermal skin tests of HIV-1 rgp160\n      MN (Immuno-AG).\n\n      Previous studies in individuals immunized with gp160  suggest that a skin test response in\n      immunized patients can be used as a surrogate marker for new proliferative and cytotoxic\n      responses induced by vaccination."
        }, 
        "brief_title": "A Phase I/II Study of Delayed-Type Hypersensitivity (DTH) Reactions to Intradermal HIV Envelope Antigen", 
        "completion_date": {
            "#text": "October 1996", 
            "@type": "Actual"
        }, 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome", 
                "Hypersensitivity", 
                "Hypersensitivity, Delayed"
            ]
        }, 
        "detailed_description": {
            "textblock": "Previous studies in individuals immunized with gp160  suggest that a skin test response in\n      immunized patients can be used as a surrogate marker for new proliferative and cytotoxic\n      responses induced by vaccination.\n\n      Patients are stratified into three groups. Fifteen patients previously immunized with\n      MicroGeneSys rgp160 antigen in ACTG 137 and not on antiretroviral therapy will receive\n      intradermal injections of Immuno-AG rgp160 IIIB (vero cell expressed) in one arm, followed 1\n      week later by intradermal injections of MicroGeneSys rgp160 IIIB (baculovirus expressed) in\n      the opposite arm (stratum 1). Forty patients who are not previously immunized with rgp160\n      will receive intradermal injections of Immuno-AG gp160 IIIB in one arm simultaneously with\n      MicroGeneSys gp160 IIIB in the opposite arm; these patients are either not on antiretroviral\n      therapy (stratum 2) or currently on antiretroviral therapy (stratum 3). All patients return\n      48 hours after each injection for skin test reading.\n\n      PER 4/5/95 AMENDMENT: Patients on all strata will re-enroll to receive Immuno-AG rgp160 MN\n      in one arm simultaneously with MicroGeneSys rgp160 IIIB in the opposite arm."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Concurrent Medication:\n\n        Allowed in Step 2 (PER 4/5/95 AMENDMENT):\n\n          -  Approved antiretroviral drugs.\n\n        Patients must have:\n\n          -  Documented HIV infection.\n\n          -  CD4 count >= 400 cells/mm3.\n\n          -  NO current active opportunistic infection or neoplasm (other than stable cutaneous\n             Kaposi's sarcoma).\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following symptoms or conditions are excluded:\n\n          -  Known hypersensitivity to insect proteins.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Antihistamine or anti-inflammatory medications for the 48-hour period between\n             injection and skin test reading.\n\n          -  Topical steroids.\n\n        Prior Medication:\n\n        PER 4/5/95 AMENDMENT -\n\n        Excluded:\n\n          -  Prior immunization with experimental HIV vaccines (strata 2 and 3 only).\n\n          -  Systemic corticosteroids, topical corticosteroids on the arms, or other systemic\n             immunosuppressant agents or antineoplastic agents within 30 days prior to study\n             entry.\n\n          -  Antihistamine or anti-inflammatory medications within 72 hours prior to intradermal\n             injections.\n\n        PREVIOUS VERSION -\n\n        Excluded within 30 days prior to study entry:\n\n          -  Any antiretroviral drugs (other than AZT, ddI, ddC, or d4T for patients in stratum\n             3).\n\n          -  Systemic corticosteroids, topical corticosteroids on the arms, or other systemic\n             immunosuppressant agents or antineoplastic agents.\n\n        Excluded within 72 hours prior to intradermal injections:\n\n          -  Antihistamine or anti-inflammatory medications."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "50", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00000782", 
            "org_study_id": "ACTG 221", 
            "secondary_id": "11198"
        }, 
        "intervention": [
            {
                "intervention_name": "gp160 Vaccine (Immuno-AG)", 
                "intervention_type": "Biological"
            }, 
            {
                "intervention_name": "gp160 Vaccine (MicroGeneSys)", 
                "intervention_type": "Biological"
            }
        ], 
        "keyword": [
            "Vaccines, Synthetic", 
            "Injections, Intradermal", 
            "HIV Antigens", 
            "HIV-1", 
            "HIV Envelope Protein gp160", 
            "Acquired Immunodeficiency Syndrome", 
            "AIDS-Related Complex", 
            "Hypersensitivity, Delayed", 
            "AIDS Vaccines", 
            "HIV Therapeutic Vaccine"
        ], 
        "lastchanged_date": "May 23, 2012", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Palo Alto", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "943055107"
                    }, 
                    "name": "Stanford CRS"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Jose", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "951282699"
                    }, 
                    "name": "Santa Clara Valley Med. Ctr."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Mateo", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "943055107"
                    }, 
                    "name": "San Mateo County AIDS Program"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10016"
                    }, 
                    "name": "NY Univ. HIV/AIDS CRS"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Phase I/II Study of Delayed-Type Hypersensitivity (DTH) Reactions to Intradermal HIV Envelope Antigen", 
        "overall_official": {
            "last_name": "Katzenstein D", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 1", 
        "reference": {
            "PMID": "10634195", 
            "citation": "Katzenstein DA, Kundu S, Spritzler J, Smoller BR, Haszlett P, Valentine F, Merigan TC. Delayed-type hypersensitivity to recombinant HIV envelope glycoprotein (rgp160) after immunization with homologous antigen. J Acquir Immune Defic Syndr. 1999 Dec 1;22(4):341-7."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00000782"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "National Institute of Allergy and Infectious Diseases (NIAID)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Institute of Allergy and Infectious Diseases (NIAID)", 
                "agency_class": "NIH"
            }
        }, 
        "study_design": "Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2012"
    }, 
    "geocoordinates": {
        "NY Univ. HIV/AIDS CRS": "40.714 -74.006", 
        "San Mateo County AIDS Program": "37.563 -122.326", 
        "Santa Clara Valley Med. Ctr.": "37.339 -121.895", 
        "Stanford CRS": "37.442 -122.143"
    }
}